Oruka Therapeutics, Inc. (ORKA)

Market Cap	699.27M
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	35.00M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	120,387
Open	21.01
Previous Close	21.13
Day's Range	19.93 - 21.05
52-Week Range	18.20 - 53.88
Beta	n/a
Analysts	Strong Buy
Price Target	43.60 (+118.22%)
Earnings Date	Feb 15, 2025

About ORKA

Oruka Therapeutics, Inc., a biotechnology company, develops novel biologics for the treatment of chronic skin diseases. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23 (IL-23p19); and ORKA-002 that targets interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of psoriasis psoriatic arthritis, and other inflammatory diseases. The company is based in Waltham, Massachusetts.

• Founded: 2004
• Country: United States
• Stock Exchange: NASDAQ
• Ticker Symbol: ORKA
• Website: https://orukatx.com

Financial Performance

Financial numbers in USD

Analyst Forecast

According to 6 analysts, the average rating for ORKA stock is "Strong Buy." The 12-month stock price forecast is $43.6, which is an increase of 118.22% from the latest price.

Price Target

$43.6

(118.22% upside)

Analyst Consensus: Strong Buy